Lift population glycemic control and close quality gaps, HEDIS, MIPS, and Stars, cutting complications and avoidable admissions across your members.
Poorly controlled diabetes drives the most expensive claims you carry, admissions, ED visits, and complications, and it drags your quality scores down with it.
Endobits gives you continuous visibility across your at-risk members, and closes the gaps that cost you most.
Continuous glucose visibility across your at-risk members, not just at claims time.
Pulls down your >9% A1c population and lifts HEDIS, MIPS, and Star measures.
Catches deterioration early, before it becomes an admission.
Fewer complications and admissions across the population.
Model flags a high probability of a severe hypoglycemia admission within 30 days. Care management is auto-notified to trigger outreach and a medication review, projected to avoid an estimated $18,000 inpatient episode.
Glycemic trend is deteriorating and this member is on track to cross the >9% HEDIS threshold. Endobits prioritizes them for a care-management touch and titration review, closing a quality gap before it lands and heads off downstream complication cost.
Rising glycemic variability puts this member on a costly trajectory. Outreach is already underway, a nurse touchpoint and adherence check are in progress to pull the member back to target and keep them out of the high-cost tier.
This member is well-controlled and low-cost. No intervention is needed, Endobits keeps them in continuous monitoring so any drift is caught early, freeing your care-management capacity for the members who move the numbers.
Illustrative. Reviewing a single member's CGM profile takes a trained reviewer roughly 30–45 minutes; Endobits stratifies an entire population in real time.
Stand up Endobits for your plan in days, no new infrastructure to deploy.
Securely connect claims and device feeds. One integration, no member disruption.
Endobits surfaces the members heading toward costly complications, before they land.
We predict, prioritize, and prevent. Your care-management team reviews the panel and approves the outreach.
Figures are illustrative and drawn from published sources; actual population dynamics vary by plan. Endobits is clinical decision-support software, not a guarantee of savings or quality outcomes.
Time figure is modeled at 10,000 covered members. Hospitalization reduction is from a peer-reviewed study of CGM-based monitoring; payback is a model from national inpatient cost data, not a guarantee of savings.
Set your covered lives and prevalence. Watch the acute-event spend curve bend as monitoring phases in over the first six months.
Illustrative model. Anchors: 49% acute-event reduction (RELIEF, above), $12,100 per diabetes stay (HCUP, above), a baseline of 0.20 acute stays per diabetic member per year, program at $9.99 per diabetic member per month, effect phased in over six months. Not a guarantee of savings.
The few drive the spend. Endobits moves members down the pyramid before they climb it.
Illustrative stratification. Tier mix and spend shares are modeled, shown for the diabetic population implied by the sliders above.
A 12-month, outcome-linked pilot on your rising-risk cohort. The goal: fewer severe events, more days in range. The proof: complication spend that never lands. Our fees follow the value delivered.
Your rising-risk diabetes members, stratified in weeks, not quarters. Panel agreed together.
Trailing 12-month acute-event rate, fixed with your actuaries before a dollar moves.
Severe events avoided. Days in range gained. Complication spend saved. Fees follow delivered value, and the outcome data is yours either way.
$9.99 per member per month, starting. Outcome-linked pricing available.
We do not sell patient data.
Tell us your covered lives and prevalence. See the diabetic population at stake and the avoidable cost you could address.
Endobits runs in live clinical deployment with a US primary-care panel today, and on consumers' phones through the Endobits Companion app. Reference conversations are available under NDA.
Ask who's using itThe engine underneath is peer-reviewed (JMIR Diabetes 2020) and independently verified by the National Research Council of Canada. The evidence.
Built to connect with